XNAS · Healthcare · Biotechnology
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
**Nasdaq delisting notice** overshadows mixed Q1 results with revenue beat offset by wider losses. Seralutinib pulmonary hypertension program faces significant funding challenges with **$80M market cap**.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Q1 2026 | -0.17 | -0.20 | -17.65% | $17.0M | ❌ Miss | -2.94% | +14.17% | — |
| 2026-05-15 | Q1 2026 | -0.17 | -0.20 | -17.65% | $17.0M | ❌ Miss | -2.74% | -38.21% | — |
| 2026-03-17 |
| Q4 2025 |
| -0.20 |
| -0.21 |
| -5.00% |
| $13.8M |
| ❌ Miss |
| -2.48% |
| -26.90% |
| -7.29% |
| 2025-11-05 | Q3 2025 | -0.19 | -0.21 | -10.53% | $13.3M | ❌ Miss | — | — | — |
| 2025-08-05 | Q2 2025 | -0.18 | -0.17 | +5.56% | $11.5M | ✅ Beat | +1.39% | -10.65% | +16.20% |
| 2025-03-13 | Q4 2024 | -0.17 | -0.15 | +11.76% | $9.4M | ✅ Beat | +11.54% | +3.85% | -37.47% |
| 2024-11-07 | Q3 2024 | -0.15 | -0.14 | +6.67% | $9.5M | ✅ Beat | -0.91% | -13.19% | -13.59% |
| 2024-08-12 | Q2 2024 | 0.23 | 0.22 | -4.35% | $95.8M | ❌ Miss | +3.81% | +17.40% | +11.96% |
Showing last 8 quarters.